Omnicell, Inc. (NASDAQ:OMCL) Receives $45.33 Average PT from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $46.7143.

Several brokerages recently weighed in on OMCL. Bank of America raised their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, May 23rd. Wells Fargo & Company raised their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, July 21st. Wall Street Zen cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Benchmark dropped their target price on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler set a $55.00 price target on Omnicell and gave the company an “overweight” rating in a research note on Monday.

Omnicell Stock Performance

NASDAQ:OMCL opened at $31.34 on Monday. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.74. The company has a fifty day simple moving average of $29.43 and a two-hundred day simple moving average of $32.52. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 62.68, a price-to-earnings-growth ratio of 9.20 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. Omnicell’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.51 EPS. As a group, equities analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. increased its position in shares of Omnicell by 2.6% during the first quarter. Principal Financial Group Inc. now owns 244,644 shares of the company’s stock worth $8,553,000 after purchasing an additional 6,288 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Omnicell during the 1st quarter worth approximately $2,073,000. Jane Street Group LLC grew its stake in Omnicell by 7.4% during the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company’s stock worth $2,417,000 after buying an additional 3,725 shares during the last quarter. Invesco Ltd. increased its position in Omnicell by 2.4% during the fourth quarter. Invesco Ltd. now owns 219,453 shares of the company’s stock worth $9,770,000 after buying an additional 5,063 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Omnicell in the first quarter valued at approximately $901,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.